Sheila Gujrathi was named Chief Strategy Officer of Bolt Biotherapeutics, Inc. As of October 28, 2026, Bolt Biotherapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on October 23, 2026, naming 2 appointments (Form 8-K, October 23, 2026).
Sell to companies like Bolt Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Bolt Biotherapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-10-23. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Bolt Biotherapeutics, Inc. files it.
Layoffs on record: about 20 jobs, latest 2025-10-02 (layoff filings and notices).
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-23 | In | Director | 8-K, 2026-10-23 | ||
| 2026-10-23 | In | Chief Strategy Officer | 8-K, 2026-10-23 |
Selling to them or working with them? See who runs Bolt Biotherapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Bolt Biotherapeutics, Inc. and the records around it.
Bolt Biotherapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Layoff notices Oct 2025
- Who owns it
Companies that share a holder
- Nan Fung Group Holdings Limited also filed stake reports on 2 other companies: Evommune, Inc. (Feb 2026), Oculis Holding AG (Nov 2025)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 32 other companies: Skye Bioscience, Inc. (Oct 2026), Atea Pharmaceuticals, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
- Renaissance Technologies LLC also filed stake reports on 46 other companies: AMERICAN PUBLIC EDUCATION INC (Aug 2026), Commercial Vehicle Group, Inc. (Aug 2026), CORCEPT THERAPEUTICS INC (Aug 2026)
Watch Bolt Biotherapeutics, Inc.
Get an email when Bolt Biotherapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Bolt Biotherapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Bolt Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bolt Biotherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Who leads Bolt Biotherapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Strategy Officer: Sheila Gujrathi, appointed (filed 2026-10-23).
- Director: Sheila Gujrathi, appointed (filed 2026-10-23).
New leaders reset buying decisions — get the Full Report on Bolt Biotherapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Bolt Biotherapeutics, Inc., with the record behind each one.
Find candidates like Director at Bolt Biotherapeutics, Inc.Every change, in the filing's words
Appointed: Sheila Gujrathi, Director
Appointment of Director In accordance with the Merger Agreement, on October 23, 2026, effective immediately after the First Effective Time, Dr. Sheila Gujrathi was appointed to the Board as a Class II director of the Board.
Appointed: Sheila Gujrathi, Chief Strategy Officer
Executive Officers In accordance with the Merger Agreement, on October 23, 2026, effective immediately after the First Effective Time, Dr. Sheila Gujrathi was appointed as the Chief Strategy Officer of the Company.
Tools for this story
Each opens in a new tab, filled in for Bolt Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.